cefradine

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	26 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	86 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	190.89 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	94 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.95 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.85 hours	Lombardo F, Berellini G, Obach RS

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-1.489		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.813		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.524	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	2.042	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	82.450	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	62.990	%	High	1
herg	hERG pIC50	4.356	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	1.950	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.589	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	71.010	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK	44
kinase-selectivity-class	AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,TEK,TGFBR1	14
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.973		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	2.046		High	1
mppb	Mouse plasma protein binding (% unbound)	77.130		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	1.466		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	68.630	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	1.262	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	90.540	%	High	1
rppb	Rat plasma protein binding (% unbound)	71.380	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	941.890	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal monitoring abnormal	64.98	51.50	8	474	194	110588623
Incubator therapy	54.59	51.50	6	476	51	110588766
Foetal arrhythmia	53.90	51.50	6	476	58	110588759

Source	Code	Description
ATC	J01DB09	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:36047	antibacterial drug
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Prostatitis	indication	9713002	DOID:14654
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Pneumonia due to Streptococcus	indication	34020007
Streptococcal tonsillitis	indication	41582007
Lower respiratory tract infection	indication	50417007
Upper respiratory infection	indication	54150009
Klebsiella cystitis	indication	60867007
Urinary tract infectious disease	indication	68566005
Haemophilus influenzae pneumonia	indication	70036007
Tonsillitis	indication	90176007	DOID:10456
Infection of bone	indication	111253001
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Pneumonia	indication	233604007	DOID:552
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Infective otitis media	indication	312218008
Infectious disorder of joint	indication	363162000
Pharyngitis	indication	405737000	DOID:2275
Infection due to Staphylococcus aureus	indication	406602003
Staphylococcus Acute Otitis Media	indication	703469002
Enterococcus Urinary Tract Infection	indication
Klebsiella Prostatitis	indication
Prevention of Perioperative Infection	indication
Proteus Prostatitis	indication
Enterococcus Prostatitis	indication
Acute nephropathy	contraindication	58574008
Pseudomembranous enterocolitis	contraindication	397683000

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

cefradine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN		IC50	5.40	WOMBAT-PK
Somatostatin receptor type 4	GPCR	P31391	SSR4_HUMAN		IC50	4.30	WOMBAT-PK
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE				WOMBAT-PK

ID	Source
4017745	VUID
N0000146111	NUI
D00264	KEGG_DRUG
2239	RXNORM
C0007738	UMLSCUI
CHEBI:3547	CHEBI
CHEMBL1604	ChEMBL_ID
DB01333	DRUGBANK_ID
38103	PUBCHEM_CID
3082	MMSL
4397	MMSL
d00053	MMSL
002718	NDDF
16791000	SNOMEDCT_US
387091007	SNOMEDCT_US
D002515	MESH_DESCRIPTOR_UI
4830	IUPHAR_LIGAND_ID
4017745	VANDF
F1BC02I72W	UNII

Dose	Unit	Route
2	g	O
2	g	P

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.77	acidic
pKa2	7.56	Basic